Categories: News

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Sequential Brands and Raytheon on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Sequential Brands Group, Inc. (NASDAQ: SQBG) and Raytheon Technologies Corporation (NYSE: RTX) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.

Sequential Brands Group, Inc. (NASDAQ: SQBG)

Bragar Eagel & Squire is investigating certain officers and directors of Sequential Brands following recent news on the Company.

On December 11, 2020, the SEC issued a press release titled “SEC Charges Sequential Brands Group Inc. with Deceiving Investors by Failing to Timely Impair Goodwill.” According to the press release, “by avoiding an impairment to its goodwill in 2016, Sequential inflated its income from operations, created a false impression of its financial condition, and misstated its financial statements and reports for almost a year.” 

Based on this news, shares of Sequential dropped sharply on the same day, to close at $16.20 per share.

For more information on our investigation into Sequential Brands go to: https://bespc.com/cases/SQBG

Raytheon Technologies Corporation (NYSE: RTX)

Bragar Eagel & Squire is investigating certain officers and directors of Raytheon Technologies Company following a class action complaint that was filed against Raytheon on October 30, 2020.

The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”); and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about our investigation into Raytheon go to: https://bespc.com/cases/RTX

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Staff

Recent Posts

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today…

16 mins ago

Justera Health Signs LOI to Acquire Popular Cannabis Brand Port North

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink:…

19 mins ago

OneMedNet Partners with Leading Clinical Trial Design and Software Company in Significant Data License Agreement

Partner’s software products and services are utilized by hundreds of life science organizations, including the…

20 mins ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production…

20 mins ago

FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.

Acquisition expected to be synergistic with FOXO’s epigenetic technology in community health and addiction recovery…

20 mins ago

Sienna Announces June Dividend

MARKHAM, Ontario, June 14, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the…

20 mins ago